Newsletters

[Journal Of Clinical Investigation] Researchers showed that RB1-loss/E2F activation sensitized cancer cells to ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, by upregulating expression of ACSL4 and enriching ACSL4-dependent arachidonic acid-containing phospholipids, which are key components of ferroptosis execution.

[Clinical Cancer Research] Scientists observed that Trop-2 can serve as a cell surface target for isolating circulating tumor cells, which may serve as a predictive biomarker for antibody drug conjugates.

[Journal Of Experimental & Clinical Cancer Research] Investigators reported the development of a novel CD46-targeted alpha therapy based on the internalizing human monoclonal antibody, YS5.

[Molecular Metabolism] Scientists investigated the role of the novel insulin/insulin-like growth factor 1 (IGF1) signaling modulator inceptor in prostate cancer.

[Biomedicine & Pharmacotherapy] Researchers investigated the effect of direct mitochondria transplantation on cancer cell proliferation and chemotherapeutic sensitivity in prostate and ovarian cancer models, both in vitro and in vivo.

[Endocrinology] Scientists mapped the interaction domains within the androgen receptor (AR) and transmembrane 4 superfamily 3 (TM4SF3) and discovered that TM4SF3 also physically interacted with AR-V7, regulating its protein stability and the viability of castration-resistant prostate cancer cells expressing AR-V7.

[Scientific Reports] Researchers showed how hormone therapy affected CACNA1D expression and CaV1.3 function.

[Nuclear Medicine And Biology] Investigators synthesized a 99mTc-labeled probe and investigated its potential for SPECT imaging of prostate cancer.

[Future Oncology] The authors provide an overview of the current systemic treatments available for metastatic castration-resistant prostate cancer and reviews studies that investigate the optimal timing for the use of radium-22.

[Bayer] The new Phase III clinical study, ARASTEP, would investigate the efficacy of darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline.

[Weill Cornell Medicine] Dr. Ekta Khurana, an associate professor of physiology and biophysics at Weill Cornell Medicine, has received a 3-year, $1.2 million grant from the United States Department of Defense to investigate how prostate cancer cells evolve to become resistant to hormone-blocking therapy.

[Communications Biology] Researchers presented a workflow for culturing organoids with morphogen gradient using a CUBE culture device, followed by sectioning samples with the CUBE to retain information on gradient direction.